The Sinopharm-backed antimicrobial drug developer received $107m in a Legend Capital-led round that took its overall funding to $255m.

Legend Capital, the venture capital firm formed by conglomerate Legend Holdings, has led a RMB700m ($107 million) series E round for China-based antimicrobial therapeutics developer MicuRx Pharmaceuticals, DealStreetAsia reported on Monday.

China Merchants Group subsidiary China Merchants Securities also took part in the round, as did Korea Investment Partners, Yingke PE, Founder H Fund, Zhongtai Ventures and Detong Capital, according to a WeChat post cited by DealStreetAsia.

MicuRx is working on antimicrobial therapeutics to treat multidrug-resistant infections. Its lead product…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn